Replies to post #7612 on 123Tom's TA study group

[blanka]

Looks like BIIB loss on CNS is now AVXL GAINS...

https://seekingalpha.com/news/3444728-biogen-eisai-bail-aducanumab-alzheimers

Biogen and Eisai bail on aducanumab in Alzheimer's
Mar. 21, 2019 7:14 AM • SA Editor Douglas W. House

Biogen (NASDAQ:BIIB) and development partner Eisai (OTCPK:ESALY) have decided to terminate two late-stage studies, ENGAGE and EMERGE, evaluating aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia.

The companies decided to pull the plug after a futility analysis showed that the studies were unlikely to meet the primary endpoints.

Certain sell-side analysts were predicting that aducanumab would be a big winner for BIIB.

The data will be submitted for presentation at future medical conferences.

BIIB, current halted, will resume trading at 7:30 am ET.